Teba L, Smailer S, Taylor H C
Metabolism. 1985 Feb;34(2):161-3. doi: 10.1016/0026-0495(85)90126-x.
Studies in vitro and in vivo have shown that thyrotropin-releasing hormone (TRH)-induced calcium ion changes in the adenohypophysial cells play an important role in release of hormones by the anterior pituitary. To determine the effect of the calcium blocker nifedipine on TRH-induced thyroid-stimulating hormone (TSH) and prolactin (PRL) release, TRH stimulation tests were performed before and after 74 hours of nifedipine therapy in ten patients. Although the magnitude of the TSH and PRL mean peak increase above baseline was slightly lower during calcium blocker administration (TSH 14.1 +/- 4.8 SEM v 16.4 +/- 4.5 SEM; PRL 37.7 +/- 4.5 SEM v 41.7 +/- 5.4 SEM), this was not statistically significant. Use of nifedipine in clinically effective doses does not appear to significantly interfere with TRH-stimulated release of TSH or PRL, in vivo.
体内和体外研究表明,促甲状腺激素释放激素(TRH)诱导腺垂体细胞内钙离子变化在前脑垂体激素释放中起重要作用。为了确定钙阻滞剂硝苯地平对TRH诱导的促甲状腺激素(TSH)和催乳素(PRL)释放的影响,对10例患者在硝苯地平治疗74小时前后进行了TRH刺激试验。虽然在服用钙阻滞剂期间,TSH和PRL平均峰值高于基线的幅度略低(TSH:14.1±4.8 SEM对16.4±4.5 SEM;PRL:37.7±4.5 SEM对41.7±5.4 SEM),但这在统计学上无显著意义。在临床上使用有效剂量的硝苯地平似乎不会在体内显著干扰TRH刺激的TSH或PRL释放。